New-onset refractory status epilepticus (NORSE) - The potential role for immunotherapy

Epilepsy and Behavior

Volumn 47, Issue , 2015, Pages 17-23

  Khawaja, Ayaz M ^a   DeWolfe, Jennifer L ^a   Miller, David W ^b   Szaflarski, Jerzy P ^a,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Chemotherapy; Immunotherapy; NORSE; Outcome; Status epilepticus

Indexed keywords

AUTOANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLUTAMATE DECARBOXYLASE ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; N METHYL D ASPARTATE ANTIBODY; PREDNISONE; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; ANTICONVULSIVE AGENT; GLUTAMATE DECARBOXYLASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE DURATION; EPILEPTIC STATE; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NEUROIMAGING; NEW ONSET REFRACTORY STATUS EPILEPTICUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PERSISTENT VEGETATIVE STATE; PLASMAPHERESIS; RETROSPECTIVE STUDY; SLOW BRAIN WAVE; STEROID THERAPY; VERY ELDERLY; YOUNG ADULT; CASE CONTROL STUDY; COMPLICATION; IMMUNOLOGY; PROSPECTIVE STUDY; SEIZURE; STATUS EPILEPTICUS; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; AUTOANTIBODIES; CASE-CONTROL STUDIES; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, N-METHYL-D-ASPARTATE; SEIZURES; STATUS EPILEPTICUS; TREATMENT OUTCOME;

EID: 84929590546     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2015.04.054     Document Type: Article

References (18)

1. Trinka E., Hofler J., Zerbs A. Causes of status epilepticus. Epilepsia 2012, 53(Suppl. 4):127-138.
2. Brophy G.M., Bell R., Claassen J., Alldredge B., Bleck T.P., Glauser T., et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012, 17:3-23.
3. Shorvon S., Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011, 134:2802-2818.
4. Kilbride R.D., Reynolds A.S., Szaflarski J.P., Hirsch L.J. Clinical outcomes following prolonged refractory status epilepticus (PRSE). Neurocrit Care 2013, 18:374-385.
5. Wilder-Smith E.P., Lim E.C., Teoh H.L., Sharma V.K., Tan J.J., Chan B.P., et al. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singapore 2005, 34:417-420.
6. Baxter P., Clarke A., Cross H., Harding B., Hicks E., Livingston J., et al. Idiopathic catastrophic epileptic encephalopathy presenting with acute onset intractable status. Seizure 2003, 12:379-387.
7. Van Lierde I., Van Paesschen W., Dupont P., Maes A., Sciot R. De novo cryptogenic refractory multifocal febrile status epilepticus in the young adult: a review of six cases. Acta Neurol Belg 2003, 103:88-94.
8. Costello D.J., Kilbride R.D., Cole A.J. Cryptogenic new onset refractory status epilepticus (NORSE) in adults - infectious or not?. J Neurol Sci 2009, 277:26-31.
9. Gall C.R., Jumma O., Mohanraj R. Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy. Seizure 2013, 22:217-220.
10. Li J., Saldivar C., Maganti R.K. Plasma exchange in cryptogenic new onset refractory status epilepticus. Seizure 2013, 22:70-73.
11. Kaneko J., Iizuka T., Asari H., Ishima D., Kasakura S., Hara A., et al. Retrospective review of 6 Patients with new-onset refractory status epilepticus (NORSE) syndrome: early intervention with intravenous cyclophosphamide may improve outcome. Neurology 2013, 80. [Meeting Abstracts 1].
12. Mikaeloff Y., Jambaque I., Hertz-Pannier L., Zamfirescu A., Adamsbaum C., Plouin P., et al. Devastating epileptic encephalopathy in school-aged children (DESC): a pseudo encephalitis. Epilepsy Res 2006, 69:67-79.
13. Kramer U., Shorer Z., Ben-Zeev B., Lerman-Sagie T., Goldberg-Stern H., Lahat E. Severe refractory status epilepticus owing to presumed encephalitis. J Child Neurol 2005, 20:184-187.
14. Sahin M., Menache C.C., Holmes G.L., Riviello J.J. Outcome of severe refractory status epilepticus in children. Epilepsia 2001, 42:1461-1467.
15. Gaspard N., Foreman B., Judd L.M., Brenton J.N., Nathan B.R., McCoy B.M., et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia 2013, 54:1498-1503.
16. Kanter I.C., Huttner H.B., Staykov D., Biermann T., Struffert T., Kerling F., et al. Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. Epilepsia 2008, 49:914-920.
17. Toledano M., Britton J.W., McKeon A., Shin C., Lennon V.A., Quek A.M., et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 2014, 82:1578-1586.
18. Ruegg S., Panzer J.A. Immune therapy for pharmacoresistant epilepsy: ready to go?. Neurology 2014, 82:1572-1573.